Can Immunity to Breast Cancer Eliminate Residual Micrometastases?

被引:16
作者
Disis, Mary L. [1 ]
Stanton, Sasha E. [1 ]
机构
[1] Univ Washington, Ctr Translat Med Womens Hlth, Tumor Vaccine Grp, Seattle, WA 98109 USA
关键词
DENDRITIC CELLS; GENE SIGNATURE; TRASTUZUMAB; EXPRESSION; HER-2/NEU; AGENTS; VACCINE; IMPACT; TUMORS;
D O I
10.1158/1078-0432.CCR-13-0734
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
An effective immune response has the potential for breast cancer sterilization with marked reduction in the potential for disease relapse. Adaptive type I immune cells uniquely have the capability of (i) cytotoxic T-cell activation and proliferation until all antigen expressing cells are eradicated, (ii) traversing endothelial barriers to penetrate tumor deposits wherever they occur, and (iii) immunologic memory, which allows the persistence of destructive immunity over the years it may take for breast cancer micrometastases to become clinically evident. Numerous recent investigations suggest that some breast cancers stimulate the type of immunity that results in a decreased risk of relapse. Moreover, the endogenous type I tumor microenvironment or type I immunity induced by drugs or biologic agents may improve response to standard therapies, further lowering the probability of disease recurrence. Clin Cancer Res; 19(23); 6398-403. (C) 2013 AACR.
引用
收藏
页码:6398 / 6403
页数:6
相关论文
共 28 条
[1]
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? [J].
Arnould, L ;
Gelly, M ;
Penault-Llorca, F ;
Benoit, L ;
Bonnetain, F ;
Migeon, C ;
Cabaret, V ;
Fermeaux, V ;
Bertheau, P ;
Garnier, J ;
Jeannin, JF ;
Coudert, B .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :259-267
[2]
Neoadjuvant Therapy as a Platform for Drug Development and Approval in Breast Cancer [J].
Bardia, Aditya ;
Baselga, Jose .
CLINICAL CANCER RESEARCH, 2013, 19 (23) :6360-6370
[3]
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion [J].
Czerniecki, Brian J. ;
Koski, Gary K. ;
Koldovsky, Ursula ;
Xu, Shuwen ;
Cohen, Peter A. ;
Mick, Rosemarie ;
Nisenbaum, Harvey ;
Pasha, Terry ;
Xu, Min ;
Fox, Kevin R. ;
Weinstein, Susan ;
Orel, Susan G. ;
Vonderheide, Robert ;
Coukos, George ;
DeMichele, Angela ;
Araujo, Louis ;
Spitz, Francis R. ;
Rosen, Mark ;
Levine, Bruce L. ;
June, Carl ;
Zhang, Paul J. .
CANCER RESEARCH, 2007, 67 (04) :1842-1852
[4]
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer [J].
Denkert, Carsten ;
Loibl, Sibylle ;
Noske, Aurelia ;
Roller, Marc ;
Mueller, Berit Maria ;
Komor, Martina ;
Budczies, Jan ;
Darb-Esfahani, Silvia ;
Kronenwett, Ralf ;
Hanusch, Claus ;
von Toerne, Christian ;
Weichert, Wilko ;
Engels, Knut ;
Solbach, Christine ;
Schrader, Iris ;
Dietel, Manfred ;
von Minckwitz, Gunter .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) :105-113
[5]
Immune Regulation of Cancer [J].
Disis, Mary L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (29) :4531-4538
[6]
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer [J].
Disis, Mary L. ;
Wallace, Danelle R. ;
Gooley, Theodore A. ;
Dang, Yushe ;
Slota, Meredith ;
Lu, Hailing ;
Coveler, Andrew L. ;
Childs, Jennifer S. ;
Higgins, Doreen M. ;
Fintak, Patricia A. ;
dela Rosa, Corazon ;
Tietje, Kathleen ;
Link, John ;
Waisman, James ;
Salazar, Lupe G. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4685-4692
[7]
Tumor Antigen-Targeted, Monoclonal Antibody-Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape [J].
Ferris, Robert L. ;
Jaffee, Elizabeth M. ;
Ferrone, Soldano .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (28) :4390-4399
[8]
The immune contexture in human tumours: impact on clinical outcome [J].
Fridman, Wolf Herman ;
Pages, Franck ;
Sautes-Fridman, Catherine ;
Galon, Jerome .
NATURE REVIEWS CANCER, 2012, 12 (04) :298-306
[9]
The secret ally: immunostimulation by anticancer drugs [J].
Galluzzi, Lorenzo ;
Senovilla, Laura ;
Zitvogel, Laurence ;
Kroemer, Guido .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) :215-233
[10]
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity [J].
Goodell, Vivian ;
Waisman, James ;
Salazar, Lupe G. ;
dela Rosa, Corazon ;
Link, John ;
Coveler, Andrew L. ;
Childs, Jennifer S. ;
Fintak, Patricia A. ;
Higgins, Doreen M. ;
Disis, Mary L. .
MOLECULAR CANCER THERAPEUTICS, 2008, 7 (03) :449-454